GERN vs ALLO

For growth investors, Geron Corporation (GERN) is the stronger pick with 138.

8% revenue growth year-over-year, versus -100. 0% for Allogene Therapeutics, Inc. (ALLO). Analysts rate Geron Corporation (GERN) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Geron Corporation (GERN) delivered a total return of +9.

8%, compared to -92. 4% for Allogene Therapeutics, Inc. (ALLO). Over 10 years, the gap is even starker: GERN returned -47. 3% versus ALLO's -90. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Geron Corporation (GERN) is the lower-risk stock at 1.

89β versus Allogene Therapeutics, Inc. 's 2. 58β — meaning ALLO is approximately 36% more volatile than GERN relative to the S&P 500. On balance sheet safety, Allogene Therapeutics, Inc. (ALLO) carries a lower debt/equity ratio of 26% versus 111% for Geron Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Geron Corporation (GERN) is pulling ahead at 138.

8% versus -100. 0% for Allogene Therapeutics, Inc. (ALLO). On earnings-per-share growth, the picture is similar: Geron Corporation grew EPS 51. 9% year-over-year, compared to 34. 1% for Allogene Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Allogene Therapeutics, Inc.

(ALLO) is the more profitable company, earning 0. 0% net margin versus -46. 7% for Geron Corporation — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALLO leads at 0. 0% versus -29. 3% for GERN. At the gross margin level — before operating expenses — GERN leads at 97. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Geron Corporation (GERN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Allogene Therapeutics, Inc. (ALLO) carries a higher beta of 2. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GERN: -47. 3%, ALLO: -90. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GERN is a small-cap high-growth stock; ALLO is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.